Bellicum Pharma (BLCM) Tops Q2 EPS by 9c

Bellicum Pharma (NASDAQ: BLCM) reported Q2 EPS of ($0.40), $0.09 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $84 thousand versus the consensus estimate of $230 thousand.

For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss